Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study.
Fiche publication
Date publication
juillet 2018
Journal
Annals of surgical oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MARCHAL Frédéric
Tous les auteurs :
Malgras B, Gayat E, Aoun O, Dico RL, Eveno C, Pautrat K, Delhorme JB, Passot G, Marchal F, Sgarbura O, Ferron G, Goéré D, Andre T, Pocard M,
Lien Pubmed
Résumé
The introduction of cytoreductive surgery (CRS) in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) improved the prognosis of selected patients with peritoneal mesothelioma (PM).
Mots clés
Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Chemotherapy, Cancer, Regional Perfusion, mortality, Cisplatin, administration & dosage, Combined Modality Therapy, Doxorubicin, administration & dosage, Erythrocyte Transfusion, mortality, Female, Follow-Up Studies, Humans, Hyperthermia, Induced, mortality, Irinotecan, administration & dosage, Lung Neoplasms, mortality, Male, Mesothelioma, mortality, Middle Aged, Mitomycin, administration & dosage, Oxaliplatin, administration & dosage, Peritoneal Neoplasms, mortality, Prognosis, Prospective Studies, Survival Rate
Référence
Ann. Surg. Oncol.. 2018 Jul 5;: